Loading organizations...
§ Private Profile · 11025 Dover St Unit 1600, Westminster, Colorado, 80021, United States
Orthobiologics company developing and commercializing bone graft products to enhance bone growth and repair for orthopedics and spine surgery.
Based in Westminster, Colorado, Cerapedics is a medical device company that develops and commercializes orthobiologic products utilizing proprietary P-15 osteogenic cell-binding peptide technology to enhance bone growth and repair. The organization's primary commercial offerings include i-FACTOR and PearlMatrix, which are regulatory-approved bone graft substitutes utilized by clinicians for complex spinal fusion and general orthopedic surgical procedures. The enterprise has steadily scaled its manufacturing and administrative operations through multiple headquarters expansions, reaching an employee count of nearly 100 personnel by the end of 2019. To finance its ongoing clinical validation and commercialization efforts, the firm has secured private equity and venture capital, highlighted by a $22 million funding round led by KCK Group in 2018. Following the sale of its predecessor entity CeraMed Dental to DENTSPLY, Cerapedics was officially established in 2001 by founder Andrew Tofe.
Cerapedics has raised $132.0M across 9 funding rounds.
Cerapedics has raised $132.0M in total across 9 funding rounds.
Cerapedics has raised $132.0M in total across 9 funding rounds.
Cerapedics's investors include Valeska Schroeder, Oxford Finance, Joe Hammer, CVF, Sam Wu, NGN Capital, OrbiMed.
Cerapedics has raised $132.0M across 9 funding rounds. Most recently, it raised $22.0M Other Equity in July 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 16, 2018 | $22M Venture Round | Valeska Schroeder | — | Announced |
| Apr 19, 2017 | $20M Debt Financing | Oxford Finance | — | Announced |
| Sep 29, 2016 | $11M Series D | — | — | Announced |
| Apr 7, 2015 | $8M Debt Financing | — | — | Announced |
| May 12, 2014 | $9M Debt Financing | JOE Hammer | — | Announced |
| Dec 12, 2012 | $19M Series C | CVF, SAM WU | NGN Capital, OrbiMed | Announced |
| Apr 1, 2009 | $15M Series B | — | OrbiMed | Announced |
| Oct 1, 2007 | $16M Series A | — | OrbiMed | Announced |
| Feb 1, 2007 | $12M Series U | — | OrbiMed | Announced |
Cerapedics is a global, commercial-stage orthopedics company specializing in orthobiologics, developing and commercializing proprietary synthetic small peptide (P-15) technology to accelerate bone repair and fusion in spinal procedures.[1][3][8] Its flagship product, i-FACTOR Peptide Enhanced Bone Graft, is FDA-approved (PMA in 2015) for cervical spinal fusion, serving surgeons and patients with degenerative disc disease by stimulating natural bone healing through cell attachment and activation, outperforming local autograft in fusion, function, neurological, and safety outcomes.[1][5][6] The company recently launched PearlMatrix P-15 Peptide Enhanced Bone Graft, FDA-approved for lumbar spinal fusion (TLIF procedures), targeting faster fusion in high-risk patients, with i-FACTOR used in over 200,000 patients globally and strong commercial growth driving facility expansions.[2][5][8]
Founded over a decade ago and headquartered in Westminster, Colorado, Cerapedics emerged from expertise in bone repair technologies, with key figures like Andrew Tofe, PhD—possessing over 40 years in bone therapeutics, 50+ publications, and patents from developing products like PepGen P-15—and Douglas Kohrs, with 35 years as a medical device founder and executive (e.g., Responsive Orthopedics acquired by Medtronic).[2][3] The idea stemmed from pioneering P-15 peptide technology, mimicking a sequence in Type I collagen for cellular attachment in bone, leading to i-FACTOR's development as a drug-device biologic.[1][6] Early traction included FDA PMA for i-FACTOR in 2015, a Premier Inc. agreement in 2016 for broader access, and rapid adoption in cervical fusion, setting the stage for expansions and next-gen products like PearlMatrix.[1][2]
Cerapedics stands out in the commoditized bone graft market (over 400 options) through its evidence-based P-15 technology and Class III FDA approvals:
Cerapedics rides the wave of advanced orthobiologics in spine surgery, addressing unmet needs in faster, higher-rate bone fusion amid rising degenerative diseases and high-risk patient volumes.[3][4] Timing aligns with FDA's push for evidence-based devices (e.g., Breakthrough Designation, PMA/IDE pathways), favoring P-15's Level I data over commoditized alternatives in a market demanding reimbursement-friendly, superior outcomes.[5][6][7] Favorable forces include surgeon demand for biologics reducing reoperations, Colorado's medtech talent pool, and global expansion potential; the company influences the ecosystem by setting paradigms in peptide-enhanced grafts, investing in studies, and elevating standards via holistic sales and clinical evidence.[2][3][6]
Cerapedics is poised for accelerated growth post-PearlMatrix launch, with expanded manufacturing, ongoing clinical investments, and potential label expansions in lumbar/international bone repair.[2][5][6] Trends like value-based care, AI-driven personalization in orthopedics, and biologics dominance will amplify its edge, potentially evolving influence through partnerships, acquisitions, or broader indications. As a leader redefining bone repair, Cerapedics exemplifies how peptide innovation delivers tangible patient impacts in a high-stakes medtech arena.[3][8]